Nautilus Biotechnolgy financials
$1.37+22.97%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$66.8M | -$81.5M | -$76.2M | -$63.6M | -$50.5M |
| Net income | -$59.0M | -$70.8M | -$63.7M | -$57.9M | -$50.3M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-0.47 | $-0.56 | $-0.51 | $-0.46 | $-0.60 |
| EBITDA | -$65.1M | -$79.4M | -$74.3M | -$60.2M | -$49.5M |
| Operating cash flow | -$50.7M | -$59.1M | -$51.7M | -$45.8M | -$39.2M |
| Free cash flow | -$52.0M | -$61.3M | -$54.2M | -$48.1M | -$41.5M |
| Diluted shares | 126.3M | 125.4M | 124.9M | 124.6M | 84.5M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $12.4M | $27.6M | $19.4M | $114.5M | $185.6M |
| Short-term investments | $91.0M | $102.2M | $154.0M | $69.9M | $160.1M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $191.1M | $242.7M | $305.6M | $350.1M | $398.4M |
| Total liabilities | $34.1M | $34.0M | $40.2M | $35.1M | $34.9M |
| Shareholders' equity | $157.0M | $208.7M | $265.4M | $314.9M | $363.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology